Lipid profiles and endothelial function with low-dose hormone replacement therapy in postmenopausal women at risk for coronary artery disease: A randomized trial

International Journal of Cardiology

Volumn 89, Issue 2-3, 2003, Pages 257-265

  Mercuro, Giuseppe ^a,b   Vitale, Cristiana ^a   Fini, Massimo ^a   Zoncu, Sandra ^a,b   Leonardo, Filippo ^a   Rosano, Giuseppe M C ^a,b  

^a IRCCS San Raffael   (Italy)

^b UNIVERSITY OF CAGLIARI   (Italy)

Author keywords

Coronary artery disease; Low dose HRT; Postmenopausal women

Indexed keywords

CHOLESTEROL; CONJUGATED ESTROGEN; CONJUGATED ESTROGEN PLUS MEDROXYPROGESTERONE ACETATE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; AGED; ARTERY BLOOD FLOW; ARTERY DILATATION; ARTICLE; BLOOD VESSEL FUNCTION; BRACHIAL ARTERY; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORONARY RISK; CROSSOVER PROCEDURE; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; ECHOGRAPHY; ESTROGEN THERAPY; FEMALE; FUNCTIONAL ASSESSMENT; HORMONE SUBSTITUTION; HUMAN; HYPEREMIA; LIPID ANALYSIS; LIPOPROTEIN BLOOD LEVEL; LOW DRUG DOSE; NORMAL HUMAN; POSTMENOPAUSE; PRESCRIPTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK BENEFIT ANALYSIS; RISK FACTOR; TRIACYLGLYCEROL BLOOD LEVEL; VASCULAR ENDOTHELIUM;

EID: 0038060318     PISSN: 01675273     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0167-5273(02)00505-3     Document Type: Article

References (38)

1. Kannel W.B., Hjortland M.C., McNamara P.M., Gordon T. Menopause and risk of cardiovascular disease. The Framingham Study. Ann. Intern. Med. 85:1976;447-452.
2. Deaths and death rates for the leading causes of death in specified age groups, by age and sex: United States, 1977. Natl Vital Stat Rep. 47:1999;27-37.
3. Barrett-Connor E., Grady D. Hormone replacement therapy, heart disease, and other considerations. Annu. Rev. Pub. Health. 19:1998;55-72.
4. Mendelsohn M.E., Karas R.H. The protective effects of estrogen on the cardiovascular system. N. Engl. J. Med. 340:1999;1801-1811.
5. Grodstein F., Manson J.E., Colditz G.A., Willett W.C., Speizer F.E., Stampfer M.J. A prospective, observational study of postmenopausal hormone therapy and primary prevention of cardiovascular disease. Ann. Intern. Med. 133:2000;933-941.
6. Hulley S., Grady D., Bush T., et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. J Am Med Assoc. 280:1998;605-613.
7. Herrington D.M., Reboussin D.M., Brosnihan K.B., et al. Effects of estrogen replacement on the progression of coronary-artery atherosclerosis. N. Engl. J. Med. 343:2000;522-529.
8. Grodstein F., Manson J.E., Stampfer M.J. Postmenopausal hormone use and secondary prevention of coronary events in the nurses' health study. A prospective, observational study. Ann. Intern. Med. 135:2001;1-8.
9. Mosca L., Collins P., Herrington D.M., et al. Hormone replacement therapy and cardiovascular disease: a statement for healthcare professionals from the American Heart Association. Circulation. 104:2001;499-503.
10. Mizunuma H., Okano H., Soda M., et al. Prevention of postmenopausal bone loss with minimal uterine bleeding using low dose continuous estrogen/progestin therapy: a 2-year prospective study. Maturitas. 27:1997;69-76.
11. Genant H.K., Lucas J., Weiss S., et al. Low-dose esterified estrogen therapy. Effects on bone, plasma estradiol concentrations, endometrium, and lipid levels. Arch. Intern. Med. 157:1997;2609-2615.
12. Lobo R.A., Bush T., Carr B.R., Pickar J.H. Effects of lower doses of conjugated equine estrogens and medroxyprogesterone acetate on plasma lipids and lipoproteins, coagulation factors, and carbohydrate metabolism. Fertil. Steril. 76:2001;13-24.
13. Lieberman E.H., Gerhard M.D., Uehata A., et al. Estrogen improves endothelium-dependent, flow-mediated vasodilation in postmenopausal women. Ann. Intern. Med. 121:1994;936-941.
14. Ettinger B. Personal perspective on low-dosage estrogen therapy for postmenopausal women. Menopause. 6:1999;273-276.
15. Speroff L., Rowan J., Symons J., Genant H., Wilborn W. for the CHART Study Group - The comparative effect on bone density, endometrium, and lipids of continuous hormones as replacement therapy (CHART Study). A randomized controlled trial. J Am Med Assoc. 276:1996;1397-1403.
16. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women: Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. J Am Med Assoc. 273:1995;199-208.
17. Rosano G.M.C., Sarais C., Zoncu S., Mercuro G. The relative effects of progesterone and progestins in hormone replacement therapy. Hum. Reprod. 15:(Suppl. 1):2000;60-73.
18. Ettinger B., Selby J., Citron J.T., VanGessel A., Ettinger V.M., Hendrickson M.R. Cyclic hormone replacement therapy using quarterly progestin. Obstet. Gynecol. 83:1994;693-700.
19. Espeland M.A., Marcovina S.M., Miller V., et al. for the PEPI investigators. Effect of postmenopausal hormone therapy on lipoprotein(a) concentration. Circulation. 97:1998;979-986.
20. Rosano G.M.C., Graziottin A., Fini M. Cardioprotective effects of ovarian hormones and the HERS in perspective. Maturitas. 34:(Suppl. 2):2000;S3-S10.
21. Su W., Campos H., Judge H., Walsh B.W., Sacks F.M. Metabolism of Apo(a) and ApoB100 of lipoprotein(a) in women: effect of postmenopausal estrogen replacement. J. Clin. Endocrinol. Metab. 83:1998;3267-3276.
22. Schlegel W., Petersdorf L.I., Junker R., Schulte H., Ebert C., von Eckardstein A. The effects of six months of treatment with a low-dose of conjugated oestrogens in menopausal women. Clin. Endocrinol. 51:1999;643-651.
23. Lobo R.A., Pickar J.H., Wild R.A., Walsh B., Hirvonen E. Metabolic impact of adding medroxyprogesterone acetate to conjugated estrogen therapy in postmenopausal women. Obstet. Gynecol. 84:1994;987-995.
24. Lieberman E.H., Gerhard M.D., Uehata A., et al. Flow-induced vasodilation of the human brachial artery is impaired in patients <40 years of age with coronary artery disease. Am. J. Cardiol. 78:1996;1210-1214.
25. Anderson T.J., Uehata A., Gerhard M.D., et al. Close relation of endothelial function in the human coronary and peripheral circulations. J. Am. Coll. Cardiol. 26:1995;1235-1241.
26. Williams J.K., Adams M.R., Herrington D.M., Clarkson T.B. Short-term administration of estrogen and vascular responses of atherosclerotic coronary arteries. J. Am. Coll. Cardiol. 20:1992;452-457.
27. Reis S.E., Gloth S.T., Blumenthal R.S., et al. Ethinyl estradiol acutely attenuates abnormal coronary vasomotor responses to acetylcholine in postmenopausal women. Circulation. 89:1994;52-60.
28. Bush D.E., Jones C.E., Bass K.M., Walters G.K., Bruza J.M., Ouyang P. Estrogen replacement reverses endothelial dysfunction in postmenopausal women. Am. J. Med. 104:1998;552-558.
29. Williams J.K., Honoré E.K., Washburn S.A., Clarkson T.B. Effects of hormone replacement therapy on reactivity of atherosclerotic coronary arteries in cynomolgus monkeys. J. Am. Coll. Cardiol. 24:1994;1757-1761.
30. McCrohon J.A., Adams M.R., McCredie R.J., et al. Hormone replacement therapy is associated with improved arterial physiology in healthy post-menopausal women. Clin. Endocrinol. 45:1996;435-441.
31. Rosano G.M.C., Leonardo F., Panina G., et al. Comparative effect of continuous combined hormone replacement therapy with either conjugated equine oestrogens plus medroxyprogesterone acetate or 17β-oestradiol plus norethisterone acetate on brachial artery blood flow [abstract]. Eur. Heart J. 19:(Suppl.):1998;681.
32. Hayashi T., Yamada K., Esaki T., et al. Estrogen increases endothelial nitric oxide by a receptor-mediated system. Biochem. Biophys. Res. Commun. 214:1995;847-855.
33. Grande M., Carlstrom K., Stege R., Pousette A., Faxen M. Estrogens increase the endothelial nitric oxide synthase (ecNOS) mRNA level in LNCaP human prostate carcinoma cells. Prostate. 45:2000;232-237.
34. Hayashi T., Yamada K., Esaki T., Mutoh E., Iguchi A. Effect of estrogen on isoforms of nitric oxide synthase: possible mechanism of anti-atherosclerotic effect of estrogen. Gerontology. 43:(Suppl. 1):1997;24-34.
35. Rosano G.M., Webb C.M., Chierchia S., et al. Natural progesterone, but not medroxyprogesterone acetate, enhances the beneficial effect of estrogen on exercise-induced myocardial ischemia in postmenopausal women. J. Am. Coll. Cardiol. 36:2000;2154-2159.
36. Eastell R. Treatment of postmenopausal osteoporosis. N. Engl. J. Med. 338:1998;736-746.
37. Hogervorst E., Williams J., Budge M., Riedel W., Jolles J. The nature of the effect of female gonadal hormone replacement therapy on cognitive function in post-menopausal women: a meta-analysis. Neuroscience. 101:2000;485-512.
38. Recker R.R., Davies K.M., Dowd R.M., Heaney R.P. The effect of low-dose continuous estrogen and progesterone therapy with calcium and vitamin D on bone in elderly women: a randomized, controlled trial. Ann. Intern. Med. 130:1999;897-904.